Clinical Outcomes in Metastatic Melanoma Patients Treated with Pembrolizumab: A Single-Center Retrospective Cohort Study | OMICS International| Abstract

Journal of Oncology Research and Treatment
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Oncol Res Treat,
  • DOI: 10.4172/aot.s4.1000001

Clinical Outcomes in Metastatic Melanoma Patients Treated with Pembrolizumab: A Single-Center Retrospective Cohort Study

Sarah Mansouri1, Stéphanie Marcil2, Jean-Philippe Dulude2, Jonathan Noujaim Liu3, Guy Leblanc2 and Mai Kim Gervais2*
1Department of Medicine, Université de Montréal, Montréal, Québec, Canada
2Division of Surgical Oncology, Hospital, Université de Montréal , Montréal, Quebec, Canada
3Division of Medical Oncology, Maisonneuve-Rosemont Hospital, Université de Montréal, Montréal, Quebec, Canada
*Corresponding Author : Mai Kim Gervais, Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Université De Montré Al, Montré Al, Quebec, Canada, Tel: 514-442-4130;, Fax: 514-252-3867, Email: [email protected]

Received Date: Aug 05, 2021 / Accepted Date: Aug 19, 2021 / Published Date: Aug 26, 2021


Objectives: The aim of this study is to review the response rate and survival outcomes of patients with stage IV melanoma treated with pembrolizumab in our center.

Methods: Patients with pathologically confirmed metastatic melanoma referred to our center from 2015 to 2017 and treated with pembrolizumab were included in this study. Follow-up consisted of clinical evaluation and FDGPET scans every 3-months. The primary outcome was the response rate of pembrolizumab. Secondary outcomes included Overall Survival (OS), Progression-Free Survival (PFS), and adverse events of pembrolizumab. Long term outcomes of patients attaining complete response for which pembrolizumab was discontinued were also analyzed. Kaplan-Meier and log-rank tests were used to calculate OS and PFS.

Results: A total of 23 patients were included in the study; 7 patients had a BRAF mutation, 16 patients received The median number of pembrolizumab cycles to achieve a Complete Response (CR) was 11 cycles. Median OS and PFS were 60 months and 28 months, respectively, with a median follow-up of 27 months. At the time of data collection, 16 patients were alive and 11 of them disease free. Grade 3 and 4 adverse events occurred in less than 13% of the patients. There were no reported pembrolizumab adverse events leading to death.

Conclusion: Our results confirmed the previously reported high response rates and complete responses of pembrolizumab in patients with metastatic melanoma. Patients with CR in whom treatment was discontinued remained disease-free for the duration of our follow-up.

Keywords: Melanoma; Metastatic; Pembrolizumab; Anti-PD1

Citation: Mansouri S, Marcil S, Dulude JP, Noujaim J, Leblanc G, et al (2021) Clincal Outcomes in Metastatic Melanoma Patients Treated with Pembrolizumab: A Single- Center Retrospective Cohort Study. J Oncol Res Treat S4: 001. Doi: 10.4172/aot.s4.1000001

Copyright: © 2021 Mansouri S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 298
  • [From(publication date): 0-0 - Jan 20, 2022]
  • Breakdown by view type
  • HTML page views: 126
  • PDF downloads: 172